News Summary:
City of Hope concluded on September 1, 2026, a retrospective analysis of pediatric and adult patients with B-ALL who received CD19-directed CAR T-cell therapy between November 2014 and October 2024, finding that cytoreduction with bridging therapy improved outcomes for those with high disease burden. Previously, on August 20, 2026, the organization discussed how folate receptor alpha (FRα), a biomarker found on ovarian cancer cells, is expanding treatment options for the disease and opening the door to new targeted therapies. Earlier, on August 17, 2026, Chief Operating Officer Annette Morgan reflected on the significant achievement of opening City of Hope Orange County’s cancer specialty hospital approximately a year prior, noting a less chaotic operational state after navigating state license surveys. This followed an August 12, 2026, announcement highlighting City of Hope’s national clinical trial model, which extends promising therapies across its sites in Southern California, Phoenix, Chicago, and Atlanta, aiming to shorten the distance between discovery and patients.
Subscribe for full access to City of Hope (CTCA)'s profile
Subscribe for full access to City of Hope (CTCA)'s products in full detail 
